These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3750162)

  • 21. P50 in uraemic patients treated by CAPD.
    Agroyannis B; Bougatsos G; Tzanatos H; Konstadinidou I; Koutsikos D; Katirtzoglou A
    Nephrol Dial Transplant; 1992; 7(10):1071-2. PubMed ID: 1331890
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
    Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tryptophan and its metabolites in patients on continuous ambulatory peritoneal dialysis and following renal transplantation.
    Qureshi AR; Lindholm B; Garcia E; Groth CG; Bergström J
    Nephrol Dial Transplant; 1994; 9(7):791-6. PubMed ID: 7526276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The present and future of continuous ambulatory peritoneal dialysis (CAPD)].
    Selgas R
    Gac Med Mex; 1993; 129(4):267-71. PubMed ID: 7926414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino-acid-based dialysis solution changes leptinemia and leptin peritoneal clearance.
    Grzegorzewska AE; Wiecek A; Mariak I; Kokot F
    Adv Perit Dial; 2000; 16():7-14. PubMed ID: 11045252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
    Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
    J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of therapeutic efficacy of continuous ambulatory peritoneal dialysis between diabetic and non-diabetic patients: three years of experience.
    Tsai TJ; Tsai HF; Wu MS; Chuang CM; Chen WY
    Taiwan Yi Xue Hui Za Zhi; 1989 Oct; 88(10):1000-7. PubMed ID: 2699488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone histology in CAPD patients: a comparison with hemodialysis and conservatively treated chronic uremics.
    Joffe P; Pódenphant J; Heaf JG
    Adv Perit Dial; 1989; 5():171-6. PubMed ID: 2577405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Continuous ambulatory peritoneal dialysis. 5-year clinical experience].
    Fuchs C; Dorn D; Bleckmann C; Gottschaldt M; Scheler F
    Dtsch Med Wochenschr; 1985 Feb; 110(5):163-7. PubMed ID: 3967602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous ambulatory peritoneal dialysis and cellular immunity.
    Giangrande A; Cantù P; Limido A; de Francesco D; Malacrida V
    Proc Eur Dial Transplant Assoc; 1983; 19():372-9. PubMed ID: 6603616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pulmonary function in uremic patients treated with continuous ambulatory peritoneal dialysis (CAPD)].
    Gómez Fernández P; Miguel Alonso JL; Sánchez Agudo L; Calatrava JM; Conesa J; Sánchez Sicilia L
    Med Clin (Barc); 1982 Sep; 79(5):219-23. PubMed ID: 7144303
    [No Abstract]   [Full Text] [Related]  

  • 32. Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis.
    Lindholm B; Alvestrand A; Fürst P; Bergström J
    Kidney Int; 1989 May; 35(5):1219-26. PubMed ID: 2770104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Charge selectivity of peritoneal transport in CAPD patients under stable states and during peritonitis].
    Nakao T; Ogura M; Okada T; Hann M; Takahashi H; Kanebayashi Y; Shino T
    Nihon Jinzo Gakkai Shi; 1996 Nov; 38(11):502-6. PubMed ID: 8958704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serial changes of serum beta-2-microglobulin in CAPD.
    Chen HC; Guh JY; Lai YH; Tsai JH
    Perit Dial Int; 1993; 13(3):238-9. PubMed ID: 8369358
    [No Abstract]   [Full Text] [Related]  

  • 35. Protein synthesis, cellular amino acids, and energy levels in CAPD patients.
    Metcoff J; Pederson J; Gable J; Llach F
    Kidney Int Suppl; 1987 Oct; 22():S136-44. PubMed ID: 3480978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of an animal model of continuous peritoneal dialysis in chronic renal impairment.
    Miller TE; Findon G; Rowe L
    Clin Nephrol; 1992 Jan; 37(1):42-7. PubMed ID: 1541064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium antagonists improve ultrafiltration in patients on continuous ambulatory peritoneal dialysis (CAPD).
    Lamperi S; Carozzi S; Nasini MG
    ASAIO Trans; 1987; 33(3):657-63. PubMed ID: 3118927
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
    Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
    Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
    J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferrokinetics in patients on CAPD: influence of CAPD on the anemia of uremia.
    Lee HB; Koh SW; Park HS
    Korean J Intern Med; 1986 Jan; 1(1):54-9. PubMed ID: 15759377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.